Clinical Trials
3 trialsNCT06136650 2026-05-27
MK-5684-004
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT04293562 2026-05-05
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Children's Oncology Group
Phase 3 Recruiting
NCT06136624 2026-05-05
OMAHA-003
Merck Sharp & Dohme LLC
Phase 3 Recruiting